50 Studies Every Neurologist Should Know

Authors:

Brand: OUP USA

ISBN: 9780199377527

248.79 zł

236.35 zł Save 12.44 zł Tax included

Lowest price within 30 days before promotion: 236.35 zł

Quantity

Available in 4-6 weeks

Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

50 Studies Every Neurologist Should Know presents key studies that shape the current clinical practice of neurology. All neurologic subspecialties are covered, with a special emphasis on neurocritical care and vascular neurology. For each study, a concise summary is presented with an emphasis on the results and limitations of the study, and its implications for practice. An illustrative clinical case concludes each review, followed by brief information on other relevantstudies. This is the first book of its kind to present a collection of the most influential clinical trials in neurology that are detailed enough to be used on rounds, but still easily digestible. It is a must-read for health care professionals and anyone who wants to learn more about the data behind clinicalpractice.

Product Details

Brand OUP USA

Reference 86325

EAN13 9780199377527

ISBN 9780199377527

Data sheet

Publication date: 2016
Issue number: 1
Cover: paperback
Pages count: 376
Dimensions (mm): 156 x 235
Weight (g): 520

Section I:: Behavioral Neurology; 1. Cholinesterase Inhibitors for Alzheimers Disease; 2. Memantine for Alzheimers Disease; Section II:: Epilepsy; 3. Lorazepam for Generalized Status Epilepticus; 4. Lamotrigine for Partial Epilepsy:: Arm A of the SANAD Trial; 5. Valproate for Generalized and Unclassifiable Epilepsy:: Arm B of the SANAD Trial; Section III:: Headache; 6. Sumatriptan for Acute Migraine; Section IV:: Neuroinfectious Disease; 7. Steroids for Bells Palsy; 8. Steroids for Acute Bacterial Meningitis; Section V:: Movement Disorders; 9. Levadopa for Parkinsons Disease; 10. Deep-Brain Stimulation for Parkinsons Disease; Section VI:: Multiple Sclerosis; 11. Oral vs. IV Steroids for Acute Relapses of Multiple Sclerosis; 12. Interferon Beta-1a for a First Demyelinating Event:: The CHAMPS Trial; 13. Glatiramer Acetate for Clinically Isolated Syndrome:: The PreCISe Trial; 14. Natalizumab for Relapsing Multiple Sclerosis:: The SENTINEL Trial; 15. Fingolimod for Relapsing Multiple Sclerosis:: The TRANSFORMS Trial; 16. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I:: The DEFINE Trial17. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II:: The CONFIRM Trial; Section VII:: Neurocritical Care; 18. Therapeutic Hypothermia for Cardiac Arrest, Part I:: The HACA Trial; 19. Therapeutic Hypothermia for Cardiac Arrest, Part II:: The Australian Trial; 20. Decompressive Craniectomy for Diffuse Traumatic Brain Injury:: The DECRA Trial; 21. Nimodipine for Subarachnoid Hemorrhage; Section VIII:: Neuromuscular Disease; 22. IVIG vs. Plasma Exchange for Guillain-Barre Syndrome; 23. IVIG vs. Plasma Exchange for Myasthenia Gravis; 24. Riluzole for Amyotrophic Lateral Sclerosis; Section IX:: Neuro-Oncology; 25. Radiotherapy Plus Temozolomide for Glioblastoma; 26. Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma; Section X:: Neuro-Ophthalmology; 27. Steroids for Acute Optic Neuritis:: The Optic Neuritis Treatment Trial; Section XI:: Neuro-Otology; 28. The Epley Maneuver for Benign Paroxysmal Positional Vertigo; Section XII:: Sleep; 29. Modafinil for Narcolepsy; 30. Continuous Dopamine Agonist for Restless Legs Syndrome; Section XIII:: Spine Disorders; 31. Early Surgery for Sciatica; 32. Surgery for Lumbar Degenerative Spondylolisthesis:: The SPORT Trial; 33. Steroids vs. No Steroids for Acute Spinal Cord Injury:: The NASCIS II Trial; Section XIV:: Vascular Neurology; 34. IV Thrombolysis 3 Hours After an Acute Ischemic Stroke:: The NINDS Trial; 35. IV Thrombolysis 3 to 4.5 Hours After an Acute Ischemic Stroke:: The ECASS III Trial; 36. Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis):: The PROACT II Trial; 37. Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis):: The IMS III Trial; 38. Endovascular Therapy for Acute Ischemic Stroke, Part III (Using Neuroimaging to Select Patients):: The MR RESCUE Trial; 39. Endovascular Therapy for Acute Ischemic Stroke, Part IV (Clinical Trial Success):: The MR CLEAN Trial; 40. Carotid Endarterectomy for Symptomatic High-Grade Carotid Stenosis:: The NASCET Trial, Part I; 41. Carotid Endarterectomy for Symptomatic Moderate Carotid Stenosis:: The NASCET Trial, Part II; 42. Carotid Endarterectomy for Asymptomatic Carotid Stenosis:: The ACAS Trial; 43. Early Aspirin for Acute Ischemic Stroke:: The CAST Trial; 44. Aspirin vs. Heparin for Acute Ischemic Stroke:: The IST Trial; 45. Dipyridamole and Asprin for Secondary Stroke Prevention:: The ESPS-2 Trial; 46. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack:: The SPARCL Trial; 47. Adjusted-Dose Warfarin for Stroke Prevention in High-Risk Atrial Fibrillation Patients:: The SPAF III Trial; 48. Dabigatran for Stroke Prevention in Atrial Fibrillation Patients:: The RE-LY Trial; 49. Apixaban for Stroke Prevention in Atrial Fibrillation Patients:: The ARISTOTLE Trial; 50. Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients:: The ROCKET AF Trial;